Skip to main content

Table 2 Prevalence of very good/good self-rated health among all PLHIV, PLHIV on antiretroviral treatment and PLHIV on antiretroviral treatment virally suppressed

From: Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study

 

All PLHIV

Very good/good self-rated health among all PLHIV

On ART

Very good/good self-rated health among PLHIV on ART

On ART virally suppressed

Very good/good self-rated health among PLHIV on ART virally suppressed

n

n

% (95% CI)

n

n

% (95% CI)

n

n

% (95% CI)

Gender

 Male

591

404

68.4 (64.4–72.1)

571

398

69.7 (65.8–73.4)

516

377

73.1 (69.0–76.8)

 Female

195

127

65.1 (58.0–71.8)

193

126

65.3 (58.1–72.0)

177

120

67.8 (60.4–74.6)

 Transgender

12

8

66.7 (34.9–90.0)

11

7

63.6 (30.8–89.1)

8

6

75.0 (34.9–96.8)

 Unknown

2

1

50.0 (1.3–98.7)

1

0

0

1

0

0

Age group (years)

  < 35

111

86

77.5 (68.6–84.9)

103

82

79.6 (70.5–86.9)

91

73

80.2 (70.6–87.8)

 35–50

282

197

69.9 (64.1–75.2)

274

194

70.8 (65.0–76.1)

240

182

75.8 (69.9–81.1)

 51–60

299

188

62.9 (57.1–68.4)

295

187

63.4 (57.6–68.9)

274

182

66.4 (60.5–72.0)

  > 60

95

60

63.2 (52.6–72.8)

92

60

65.2 (54.6–74.9)

87

59

67.8 (56.9–77.4)

 Unknown

13

9

69.2 (38.6–90.9)

12

8

66.7 (34.9–90.1)

10

7

70.0 (34.8–93.3)

Educational level

 Illiteracy/Primary education

327

189

57.8 (52.2–63.2)

319

188

58.9 (53.3–64.4)

285

176

61.8 (55.8–67.4)

 Secondary education

258

183

70.9 (65.0–76.4)

252

180

71.4 (65.4–76.9)

229

172

75.1 (69.0–80.6)

 University education

180

150

83.3 (77.1–88.5)

171

146

85.4 (79.2–90.3)

159

139

87.4 (81.2–92.1)

 Unknown

35

18

51.4 (34.0–68.6)

34

17

50.0 (32.4–67.6)

29

16

55.2 (35.7–73.6)

Country of birth

 Spain

631

412

65.3 (61.4–69.0)

613

406

66.2 (62.3–70.0)

566

390

68.9 (64.9–72.7)

 Other

164

123

75.0 (67.7–81.4)

158

120

76.0 (68.5–82.4)

132

109

82.6 (75.0–88.6)

 Unknown

5

5

100.0 (−)

5

5

100 (48.0–100)

4

4

100 (39.8–100)

Residence

 Living with family

478

330

69.0 (63.4–71.9)

467

326

69.8 (65.4–73.9)

428

309

72.2 (67.7–76.4)

 Living alone

216

142

65.7 (59.0–72.0)

208

139

66.8 (60.0–73.2)

188

136

72.3 (65.4–78.6)

 Closed institutions/Prison/ Homeless

31

11

35.5 (19.2–54.6)

31

11

35.5 (19.2–54.6)

25

9

36.0 (18.0–57.5)

 Other

70

56

80.0 (68.7–88.6)

65

54

83.1 (71.7–91.2)

59

48

81.4 (69.1–90.3)

 Unknown

5

1

20.0 (0.5–71.6)

5

1

20.0 (0.5–71.6)

2

1

50.0 (1.2–98.7)

Employment status

 Employed

430

353

82.1 (78.1–85.6)

421

348

82.7 (78.7–86.2)

389

333

85.6 (81.7–88.9)

 Unemployed

139

65

46.8 (38.3–55.4)

126

61

48.4 (39.4–57.5)

105

54

51.4 (41.5–61.3)

 Retired/disabled

184

86

46.7 (39.4–54.2)

182

86

47.2 (39.8–54.8)

167

82

49.1 (41.3–56.9)

 Student

23

20

87.0 (66.4–97.2)

23

20

87.0 (66.4–97.2)

22

19

86.4 (65.1–97.1)

 Other/ unknown

24

16

66.7 (44.7–84.4)

24

16

66.7 (44.7–84.4)

19

15

78.9 (54.4–93.9)

Mode of transmission

 Heterosexual

246

171

69.5 (63.3–75.2)

240

168

70.0 (63.8–75.7)

216

161

74.5 (68.2–80.2)

 MSM

293

228

77.8 (72.6–82.4)

282

223

79.1 (73.9–83.7)

260

210

80.8 (75.4–85.4)

 PWID

195

101

51.8 (44.5–59.0)

192

101

52.6 (45.3–59.8)

169

95

56.2 (48.4–63.8)

 Other/ unknown

66

40

60.6 (47.8–72.4)

62

39

62.9 (49.7–74.8)

57

37

64.9 (51.1–77.1)

HIV infection stage

 Asymptomatic

386

299

77.5 (73.0–81.5)

378

296

78.3 (73.8–82.4)

353

280

79.3 (74.7–83.4)

 Symptomatic non AIDS

126

80

63.5 (54.4–71.9)

122

77

63.1 (53.9–71.7)

111

72

64.9 (55.2–73.7)

 AIDS

267

144

53.9 (47.8–60.0)

257

143

55.6 (49.3–61.8)

224

141

63.0 (56.3–69.3)

 Unknown

21

17

80.9 (58.1–94.6)

19

15

78.9 (54.4–93.9)

14

10

71.4 (41.9–91.6)

Viral load < 200 copies/ml (last determination)

 Yes

704

503

71.4 (68.0–74.8)

702

503

71.6 (68.2–75.0)

 No

71

24

33.8 (23.0–46.0)

56

17

30.4 (18.8–44.0)

 Unknown

25

13

52.0 (31.3–72.2)

18

11

61.1 (35.7–82.7)

CD4 count (last determination)

  < 200

67

14

20.9 (11.9–32.6)

61

12

19.7 (10.6–31.8)

36

10

27.8 (14.2–45.2)

 200–349

92

48

52.2 (41.5–62.7)

89

47

52.8 (51.9–63.5)

76

91

59.2 (47.3–70.4)

 350–499

116

71

61.2 (51.7–70.1)

112

68

60.7 (51.0–69.8)

99

60

60.6 (50.2–70.3)

  > =500

499

391

78.4 (74.5–81.9)

496

391

78.8 (75.0–82.3)

483

381

78.9 (75.0–82.4)

 Unknown

26

16

61.5 (40.6–79.8)

18

13

72.2 (46.5–90.3)

8

7

87.5 (47.3–99.7)

Comorbidities

 Yes

88

29

33.0 (23.3–43.8)

87

29

33.3 (23.6–44.3)

72

27

37.5 (26.4–49.7)

 No/ Unknown

712

511

71.8 (66.3–75.0)

689

502

72.9 (69.3–76.1)

630

476

75.6 (72.0–78.9)

Antiretroviral treatment

 Yes

776

531

68.4 (65.0–71.7)

 No

18

8

44.4 (21.5–69.2)

 Unknown

6

1

16.7 (0.4–64.1)

Adherence

 Optimal

653

471

72.1 (68.5–75.5)

653

471

72.1 (68.5–75.5)

611

451

73.8 (70.1–77.3)

 Suboptimal

68

36

52.9 (40.4–65.1)

68

36

52.9 (40.4–65.2)

56

31

55.4 (41.5–68.7)

 Very bad

25

3

12.0 (2.5–31.2)

25

3

12.0 (2.5–31.2)

8

1

12.5 (3.2–52.7)

 Unknown

30

21

70.0 (50.6–85.2)

30

21

70.0 (50.6–85.3)

27

20

74.1 (53.7–88.9)

 No/unknown ART

24

9

37.5 (18.8–59.4)

Years since HIV diagnosis

  < 2

73

42

57.5 (45.4–69.0)

59

34

57.6 (44.1–70.4)

38

27

71.1 (54.1–84.6)

 2–5

111

86

77.5 (68.6–84.8)

109

86

78.9 (70.0–86.1)

99

81

81.8 (72.3–88.6)

 6–10

121

93

76.9 (68.3–84.0)

120

93

77.5 (69.0–84.6)

110

89

80.9 (72.3–87.8)

 11–15

111

77

69.4 (59.9–77.8)

110

77

70.0 (60.5–78.4)

104

75

72.1 (62.5–80.5)

  > 15

374

233

62.3 (57.2–67.2)

369

233

63.1 (58.0–68.1)

345

225

65.2 (60.0–70.2)

 Unknown

10

9

90.0 (55.5–99.7)

9

8

88.9 (51.7–99.7)

6

6

100 (54.1–100)

Total

800

540

67.5 (64.1–70.7)

776

531

68.4 (65.0–71.7)

702

503

71.7 (68.2–75.0)

  1. 95% CI Confidence interval 95%, PLHIV People living with HIV, ART antiretroviral treatment, MSM Men who have sex with men, PWID People who injected drugs